Ophthal

Your Article Summary

See Latest Articles

Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' Phase I investigation
British Journal of Clinical Pharmacology, 08/13/09

Kain H et al. – The tolerability profile obtained from this study suggests that GS–101 is safe for human use. Further clinical evaluations in diseases related to abnormal angiogenesis are being targeted. In particular, the neovascularization–related orphan indications of corneal graft rejection, retinopathy of pre–maturity and neovascular glaucoma are currently under Phase II clinical investigation and are showing promising results.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of oral azithromycin in the treatment of chlamydial conjunctivitis
Eye, 11/09/09

Central Corneal Thickness During Treatment With Travoprost 0.004% in Glaucoma Patients
Journal of Ocular Pharmacology and Therapeutics, 11/02/09

Retinal function in patients treated with tamoxifen
Documenta Ophthalmologica, 11/16/09

See All of Clinical Pharmacology

Today in Glaucoma...keeping you current

Receive free subspecialty "5-minute updates" via email

Central Corneal Thickness During Treatment With Travoprost 0.004% in Glaucoma Patients
Journal of Ocular Pharmacology and Therapeutics, 11/02/09

Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma
Clinical Ophthalmology, 11/23/09

Intravitreal Bevacizumab for Neovascular Glaucoma
Journal of Ocular Pharmacology and Therapeutics, 10/30/09

See All of Glaucoma